Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1550188 · 2 trials · 1 indication
Systolic and diastolic blood pressure, pulse rate, body temperature
CD20+, immunoglobulin
Presence of anti belimumab antibody
ECGs, clinical laboratory test, local tolerance evaluation (injection site), and adverse events
Number of subjects with adverse events (AE) as meaasure of safety and tolerability
| Arm | Type | Description |
|---|---|---|
| GSK1550188 200mg for SC | ACTIVE_COMPARATOR | Single SC dose of belimumab 200mg |
| GSK1550188 200mg for IV | ACTIVE_COMPARATOR | Single IV dose of belimumab 200 mg |
| GSK1550188 1mg/kg or 10mg/kg | EXPERIMENTAL | one shot IV |
| Name | Type | Description |
|---|---|---|
| GSK1550188 IV | DRUG | Single IV dose of belimumab 200 mg |
| GSK1550188 SC | DRUG | Single SC dose of belimumab 200mg |
| GSK1550188 1mg/kg or 10mg/kg | DRUG | IV one shot |
Inclusion Criteria: * Healthy as defined as being free from clinically significant illness or disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital sign, laboratory tests and ECG. Rationale: Set for the...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
GSK1550188 is an investigational small molecule being developed for systemic lupus erythematosus (SLE). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. Two Phase 1 studies have been completed in Japanese subjects with SLE.
GSK1550188 is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in patients with systemic lupus erythematosus.
GSK1550188 is in Phase 1 clinical development. Two Phase 1 studies have been completed, both involving Japanese subjects with systemic lupus erythematosus. The drug remains investigational and is not yet approved for any use.
GSK1550188 has been studied in two completed Phase 1 trials: NCT01381536, a study in Japanese subjects with systemic lupus erythematosus, and NCT01516450, a Japanese Phase 1 study of belimumab comparing intravenous and subcutaneous administration. Both trials have been completed.
GSK1550188 is a distinct investigational small molecule being developed for systemic lupus erythematosus. One of its completed trials, NCT01516450, is titled as a study of belimumab, suggesting a possible relationship, but the drug is not identified as the same compound in the available data.